Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study

British Journal of Clinical Pharmacology

Volumn 79, Issue 3, 2015, Pages 514-522

  Hu, Xiao ^a   Cui, Yue ^a   White, Joleen ^a   Zhu, Ying ^a   Deykin, Aaron ^a   Nestorov, Ivan ^a   Hung, Serena ^a  

^a BIOGEN   (United States)

Author keywords

interferon beta 1a; multiple sclerosis; pegylation

Indexed keywords

NEOPTERIN; PEGINTERFERON BETA1A; PLACEBO; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT; MACROGOL DERIVATIVE; NEUTRALIZING ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT DURATION; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIBODIES, NEUTRALIZING; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEOPTERIN; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930011481     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12521     Document Type: Article

References (20)

1. Plegridy (peginterferon beta-1a) Package Insert. Cambridge, MA: Biogen Idec Inc., 2014.
2. Plegridy (Peginterferon beta-1a) Package Insert. Maidenhead, Berkshire, UK: Biogen Idec Inc., 2014.
3. Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, Zhu Y, Crossman M, Nestorov I, Gronke RS, Baker DP, Rogge M, Subramanyam M, Davar G,. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol 2012; 52: 798-808.
4. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A,. Pegylated interferon beta-1a in relapsing-remitting multiple sclerosis: results from ADVANCE, a randomized, phase 3, double-blind study. Lancet Neurol 2014; 13: 657-665.
5. Kurtzke JF,. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
6. Hu X, Seddighzadeh A, Stecher S, Miller L, Zhu Y, Hung S,. PEGylated interferon beta-1a pharmacokinetics, pharmacodynamics, and safety in subjects with normal or impaired renal function. Neurology 2012; 78: P06.165.
7. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
8. Rebif® (IFN Beta-1a) Package Insert. Rockland, MA: EMD Serono, Inc., 2013.
9. Fishburn CS,. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97: 4167-4183.
10. PegIntron® (Peginterferon alfa-2b) Package Insert. Whitehouse Station, NJ: Merck, 2003.
11. PEGASYS (Peginterferon alfa-2a) Package Insert. South San Francisco, CA: Genentech, Inc., 2013.
12. FDA [Internet]. Guidance for Industry Population Pharmacokinetics. Rockville, MD: U.S. Department of Health and Human Services Food and Drug Administration, 1999 [updated 1999 February]. Available at http://www.fda.gov/downloads/Drugs/Guidances/UCM072137.pdf (last accessed 22 July 2014).
13. Sheiner LB, Beal SL,. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980; 8: 553-571.
14. Sheiner LB, Beal SL,. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981; 9: 635-651.
15. Sheiner LB, Beal SL,. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983; 11: 303-319.
16. Steimer JL, Mallet A, Golmard JL, Boisvieux JF,. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev 1984; 15: 265-292.
17. Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, Biollaz J,. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 1999; 99: 131-141.
18. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ,. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther 2003; 306: 262-270.
19. Pestka S, Langer JA, Zoon KC, Samuel CE,. Interferons and their actions. Annu Rev Biochem 1987; 56: 727-777.
20. Liberati AM, Fizzotti M, Proietti MG, Di Marzio R, Schippa M, Biscottini B, Senatore M, Berruto P, Canali S, Peretti G,. Biochemical host response to interferon-beta. J Interferon Res 1988; 8: 765-777.